Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study

Jurado, Manuel; Mata, Claudia De La; Ruiz-Garcia, A.; López-Fernández, Elisa; Espinosa, Olga; Remigia, María José; Moratalla, Lucía; Goterris, Rosa; García-Martín, Paloma; Ruiz‐Cabello, Francisco; Garzón, Sebastián; Pascual, Marı́a; Espigado, Ildefonso; Solano, Carlos

doi:10.1016/j.jcyt.2017.05.002

Cited by 55 publications

(44 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wang, Ma, et al, 2018) Bone and cartilage diseases (Jo et al, 2014;Kastrinaki et al, 2013) Autoimmune diseases (Xu, 2018;W. Zhang, Feng, et al, 2018) Amyotrophic lateral sclerosis (Bonafede & Mariotti, 2017) Diabetes (Evangelista et al, 2018;Gabr et al, 2018) Glaucoma (Manuguerra-Gagne et al, 2013;Osborne, Sanderson, & Martin, 2018;Roubeix et al, 2015) Graft vs host disease (Jurado et al, 2017;Zhao et al, 2015) Intervertebral disc disease (Ahn et al, 2015;Beeravolu et al, 2018;Pereira et al, 2016;Perez-Cruet et al, 2018) Multiple sclerosis (Harris et al, 2018;Nasri et al, 2018;Planchon et al, 2018) Myocardial infarction ( investigated for the treatment of chronic tissue ulcers caused by diabetes. Patients were administered with MSCs for skin healing showed an improvement in microvascularisation structure (Kirana et al, 2012).…”

Section: Promising Applications Referencementioning

confidence: 99%

Mesenchymal stem cells: Cell therapy and regeneration potential

Brown

McKee

Bakshi

et al. 2019

J Tissue Eng Regen Med

431

310

View full text Add to dashboard Cite

Rapid advances in the isolation of multipotent progenitor cells, routinely called mesenchymal stromal/stem cells (MSCs), from various human tissues and organs have provided impetus to the field of cell therapy and regenerative medicine. The most widely studied sources of MSCs include bone marrow, adipose, muscle, peripheral blood, umbilical cord, placenta, fetal tissue, and amniotic fluid. According to the standard definition of MSCs, these clonal cells adhere to plastic, express cluster of differentiation (CD) markers such as CD73, CD90, and CD105 markers, and can differentiate into adipogenic, chondrogenic, and osteogenic lineages in vitro. However, isolated MSCs have been reported to vary in their potency and self‐renewal potential. As a result, the MSCs used for clinical applications often lead to variable or even conflicting results. The lack of uniform characterization methods both in vitro and in vivo also contributes to this confusion. Therefore, the name “MSCs” itself has been increasingly questioned lately. As the use of MSCs is expanding rapidly, there is an increasing need to understand the potential sources and specific potencies of MSCs. This review discusses and compares the characteristics of MSCs and suggests that the variations in their distinctive features are dependent on the source and method of isolation as well as epigenetic changes during maintenance and growth. We also discuss the potential opportunities and challenges of MSC research with the hope to stimulate their use for therapeutic and regenerative medicine.

show abstract

Section: Promising Applications Referencementioning

confidence: 99%

Mesenchymal stem cells: Cell therapy and regeneration potential

Brown

McKee

Bakshi

et al. 2019

J Tissue Eng Regen Med

431

310

View full text Add to dashboard Cite

show abstract

“…Ten patients completed the trial within 56 weeks were able to stop hormones, 8 of whom achieved complete remission, 2 partial remissions. The clinical efficacy after the application of AT-MSCs showed significant superiority over the historical control group treated only by cyclosporine or tacrolimus and prednisone [94]. Zhang et al enrolled a steroid refractory GVHD patient with nephrotic syndrome (NS) 10 months after allo-HSCT in 2017.…”

Section: Application In Chronic Graft-versus-host Disease (Cgvhd)mentioning

confidence: 99%

“…Dotoli et al reported that of the 3 patients with hormone-resistant III-IV aGVHD who completely resolved after MSC treatment, 1 died of tumor recurrence [87]. According to the clinical trial of Jurado, MSCs were used for the first-line treatment of cGVHD, no tumor recurrence or infection was fatal, but 2 cases had severe viral infection and 1 case had bacterial infection [94]. In a retrospective study, Blennow et al have found that the administration of MSCs was a risk factor for invasive fungal infections [101].…”

Section: Limitations Of Mscs Clinical Applicationmentioning

confidence: 99%

Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease

et al. 2020

View full text Add to dashboard Cite

It is well acknowledged that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for numerous malignant blood diseases, which has also been applied to autoimmune diseases for more than a decade. Whereas graft-versus-host disease (GVHD) occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a common serious complication, seriously affecting the efficacy of transplantation. Mesenchymal stem cells (MSCs) derived from a wealth of sources can easily isolate and expand with low immunogenicity. MSCs also have paracrine and immune regulatory functions, leading to a broad application prospect in treatment and tissue engineering. This review focuses on immunoregulatory function of MSCs, factors affecting mesenchymal stem cells to exert immunosuppressive effects, clinical application of MSCs in GVHD and researches on MSC-derived extracellular vesicles (EVs). The latest research progress on MSC in related fields is reviewed as well. The relevant literature from PubMed databases is reviewed in this article.

show abstract

“…Research from our and other laboratories has shown that MSCs could facilitate engraftment of HSCs and treat steroid-resistant acute GVHD as well [66,67]. Both BM-MSCs and ASCs have proved to be effective for the prevention and treatment of GVHD, according to the preliminary phase I/II clinical studies [68][69][70]. These advantages mentioned above make ASCs a promising candidate to promote hematopoietic reconstitution.…”

Section: Application Of Ascs and Future Perspectivesmentioning

confidence: 99%

Adipose-derived stromal cells in regulation of hematopoiesis

et al. 2020

View full text Add to dashboard Cite

Over the past decade, mesenchymal stromal cells (MSCs) found in the bone marrow microenvironment have been considered to be important candidates in cellular therapy. However, the application of MSCs in clinical settings is limited by the difficulty and low efficiency associated with the separation of MSCs from the bone marrow. Therefore, distinct sources of MSCs have been extensively explored. Adipose-derived stromal cells (ASCs), a cell line similar to MSCs, have been identified as a promising source. ASCs have become increasingly popular in many fields, as they can be conveniently extracted from fat tissue. This review focuses on the properties of ASCs in hematopoietic regulation and the underlying mechanisms, as well as the current applications and future perspectives in ASC-based therapy.

show abstract

Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study

Cited by 55 publications

References 44 publications

Mesenchymal stem cells: Cell therapy and regeneration potential

Mesenchymal stem cells: Cell therapy and regeneration potential

Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease

Adipose-derived stromal cells in regulation of hematopoiesis

Contact Info

Product

Resources

About